A Signaling Nexus for Both Good and Ill, It’s Pathways of Pathogenic and Therapeutic Importance Are Still Being Identified A recent paradigm shift in medicine started with the finding that several ...

Yale researchers have identified a particular immune response pathway that leads to severe illness and death in people infected by the SARS-CoV-2 virus. The study was published as a preprint ...

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading infectious threat to public health worldwide. It is estimated to have infected 2–3 billion people and ...

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading infectious threat to public health worldwide. It is estimated to have infected 2–3 billion people and ...

Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damage NLRP3 inflammasomes were extensively activated in ...

Age related macular degeneration, or AMD, is the leading cause of vision loss and blindness among older adults in the United States. Current treatments mainly target late stage disease, often once ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

Analysis of human samples and mouse models shows inflammasome signaling drives bone resorption in males but not females, ...

"Enrolment concludes for Inflammasome’s K8 Phase II trial for GA" was originally created and published by Clinical Trials ...

Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, announced ...